Anixa Biosciences, Inc.

NasdaqCM:ANIX Lagerbericht

Marktkapitalisierung: US$89.5m

Anixa Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Für Anixa Biosciences wird ein Gewinn- und Umsatzwachstum von 45.3% bzw. 73.4% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 47.2% pro Jahr steigen soll.

Wichtige Informationen

45.3%

Wachstumsrate der Gewinne

47.18%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.5%
Wachstumsrate der Einnahmen73.4%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert01 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
Analyseartikel • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
Analyseartikel • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
Analyseartikel • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Analyseartikel • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Analyseartikel • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
Analyseartikel • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Jan 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ANIX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
10/31/2028N/A-15N/AN/A3
10/31/2027N/A-14N/AN/A3
10/31/2026N/A-13N/AN/A4
1/31/2026N/A-10-7-7N/A
10/31/2025N/A-11-7-7N/A
7/31/2025N/A-11-7-7N/A
4/30/2025N/A-12-8-8N/A
1/31/2025N/A-12-8-8N/A
10/31/2024N/A-13-7-7N/A
7/31/2024N/A-12-8-8N/A
4/30/2024N/A-12-7-7N/A
1/31/20240-11-7-7N/A
10/31/20230-10-6-6N/A
7/31/20230-11-6-6N/A
4/30/20230-11-6-6N/A
1/31/2023N/A-12-7-7N/A
10/31/2022N/A-14-6-6N/A
7/31/20220-14-6-6N/A
4/30/20220-16-6-6N/A
1/31/20220-15-5-5N/A
10/31/20211-13-5-5N/A
7/31/20211-11-5-5N/A
4/30/20211-9-5-5N/A
1/31/20211-10-5-5N/A
10/31/2020N/A-10-6-6N/A
7/31/2020N/A-10-6-6N/A
4/30/2020N/A-9-5-5N/A
1/31/20200-9-6-5N/A
10/31/20190-12N/A-5N/A
7/31/20190-15N/A-4N/A
4/30/20191-18N/A-5N/A
1/31/20191-17N/A-4N/A
10/31/20181-14N/A-4N/A
7/31/20181-10N/A-4N/A
4/30/20181-7N/A-4N/A
1/31/20180-5N/A-4N/A
10/31/20170-7N/A-4N/A
7/31/20171-6N/A-4N/A
4/30/20170-6N/A-3N/A
1/31/20170-7N/A-4N/A
10/31/20160-5N/A-3N/A
7/31/20160-5N/A-4N/A
4/30/20160-6N/A-3N/A
1/31/20160-7N/A-4N/A
10/31/20150-1N/A1N/A
7/31/20152-3N/A2N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ANIX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ANIX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ANIX in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/20 09:18
Aktienkurs zum Tagesende2026/05/20 00:00
Gewinne2026/01/31
Jährliche Einnahmen2025/10/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Anixa Biosciences, Inc. wird von 6 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Ilya ZubkovFreedom Broker